A Phase 1, Single-Dose, Randomized, Group Sequential Cross-Over Study Evaluating the Bioavailability and Food Effect of Three Formulations of Veliparib on Pharmacokinetics in Subjects With Solid Tumors.

Trial Profile

A Phase 1, Single-Dose, Randomized, Group Sequential Cross-Over Study Evaluating the Bioavailability and Food Effect of Three Formulations of Veliparib on Pharmacokinetics in Subjects With Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Sep 2014

At a glance

  • Drugs Veliparib (Primary)
  • Indications Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 10 Jan 2012 Actual end date (November 2011) added as reported by ClinicalTrials.gov record (Extension trial: NCT01193140).
    • 10 Jan 2012 Actual end date (November 2011) added as reported by ClinicalTrials.gov record (Extension trial: NCT01193140).
    • 10 Jan 2012 Actual start date (July 2010) added as reported by ClinicalTrials.gov record (Extension trial: NCT01193140).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top